SOUTH SAN FRANCISCO, Calif. , Feb. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced the promotion of Amy C. Peterson , M.D., to the position of president and chief operating officer,

SOUTH SAN FRANCISCO, Calif. , Jan. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that on January 18, 2022 , the Company granted four new employees options to purchase a total of 127,000 shares of

- CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic - SOUTH SAN FRANCISCO, Calif. , Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics,

SOUTH SAN FRANCISCO, Calif. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics , Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy , D.Phil ., president, chief executive officer, and chairman, will present virtually at the 40